TickerStat.comwe like data

UroGen Pharma Ltd. (URGN)

Price$43.72Cached quote
URGNNasdaq
Loading local price history

Financial charts

Revenue

Net income

Total cash / debt

CashTotal debt

Financial statements

11 annual periodsNewest to oldest
20252024202320222021202020192018201720162015
Revenue$109.8M$90.4M$82.7M$64.4M$48.0M$11.8M$18,000$1.1M$8.2M$17.5M—
Gross profit$97.3M$81.5M$73.4M$56.7M$42.9M$10.8M$18,000−$675,000$7.6M$17.5M—
Gross margin88.66%90.18%88.68%88.11%89.27%91.45%100.00%−59.84%92.65%99.84%—
Research & development$67.1M$57.1M$45.6M$52.9M$47.6M$47.3M$49.3M$36.9M$18.7M——
Operating expenses$222.2M$178.3M$138.9M$135.7M$135.2M$137.5M$109.5M$76.5M$27.5M$16.7M—
Operating income−$124.9M−$96.8M−$65.5M−$79.0M−$92.3M−$126.7M−$109.5M−$77.2M−$19.9M$798,000−$12.4M
Operating margin−113.73%−107.06%−79.23%−122.82%−192.11%−1,074.15%−608,211.11%−6,842.20%−244.55%4.55%—
EBITDA−$124.6M−$96.5M−$64.7M−$78.1M−$91.5M−$126.3M−$109.2M−$76.8M−$19.8M$998,000−$12.3M
EBITDA margin−113.45%−106.70%−78.26%−121.38%−190.38%−1,070.62%−606,544.44%−6,806.74%−242.09%5.69%—
Net income−$153.5M−$126.9M−$102.2M−$109.8M−$110.8M−$128.5M−$105.1M−$75.7M−$20.0M−$1.9M−$12.7M
Net profit margin−139.81%−140.35%−123.61%−170.58%−230.67%−1,088.94%−584,144.44%−6,707.18%−245.16%−11.07%—
Basic EPSper basic share-$3.19-$2.96-$3.55-$4.81-$4.96-$5.90-$5.12-$4.80-$2.14-$1.91-$5.88
Diluted EPSper diluted share-$3.19-$2.96-$3.55-$4.79-$4.96-$5.90-$5.12-$4.80-$2.14-$1.91-$5.88
Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026
RTW INVESTMENTS, LP · 9.30% of listed sharesBlackRock, Inc. · 6.55% of listed sharesMORGAN STANLEY · 5.27% of listed sharesKynam Capital Management, LP · 4.98% of listed sharesJefferies Financial Group Inc. · 4.50% of listed sharesSG Americas Securities, LLC · 4.20% of listed sharesAMERICAN CENTURY COMPANIES INC · 3.45% of listed sharesACORN CAPITAL ADVISORS, LLC · 3.42% of listed sharesPoint72 Asset Management, L.P. · 3.12% of listed sharesFRONTIER CAPITAL MANAGEMENT CO LLC · 3.09% of listed sharesOpaleye Management Inc. · 2.95% of listed sharesSILVERARC CAPITAL MANAGEMENT, LLC · 2.66% of listed sharesMENORA MIVTACHIM HOLDINGS LTD. · 2.36% of listed sharesD. E. Shaw & Co., Inc. · 2.34% of listed sharesSTATE STREET CORP · 2.05% of listed sharesMPM BIOIMPACT LLC · 1.91% of listed sharesSoleus Capital Management, L.P. · 1.70% of listed sharesGOLDMAN SACHS GROUP INC · 1.68% of listed sharesMigdal Insurance & Financial Holdings Ltd. · 1.58% of listed sharesORBIMED ADVISORS LLC · 1.38% of listed shares
9.30%of listed shares
RTW INVESTMENTS, LP4.54M shares · Jun 30, 2026
View holders
Top 20 reported holders of URGN
Holder% owned
RTW INVESTMENTS, LP
9.30%4.54M shares
BlackRock, Inc.
6.55%3.2M shares
MORGAN STANLEY
5.27%2.58M shares
Kynam Capital Management, LP
4.98%2.43M shares
Jefferies Financial Group Inc.
4.50%2.2M shares
SG Americas Securities, LLC
4.20%2.05M shares
AMERICAN CENTURY COMPANIES INC
3.45%1.69M shares
ACORN CAPITAL ADVISORS, LLC
3.42%1.67M shares
Point72 Asset Management, L.P.
3.12%1.53M shares
FRONTIER CAPITAL MANAGEMENT CO LLC
3.09%1.51M shares
Opaleye Management Inc.
2.95%1.44M shares
SILVERARC CAPITAL MANAGEMENT, LLC
2.66%1.3M shares
MENORA MIVTACHIM HOLDINGS LTD.
2.36%1.15M shares
D. E. Shaw & Co., Inc.
2.34%1.15M shares
STATE STREET CORP
2.05%1M shares
MPM BIOIMPACT LLC
1.91%933.42K shares
Soleus Capital Management, L.P.
1.70%829.81K shares
GOLDMAN SACHS GROUP INC
1.68%819.83K shares
Migdal Insurance & Financial Holdings Ltd.
1.58%770.91K shares
ORBIMED ADVISORS LLC
1.38%676.19K shares

Percentages use 48.87M shares of this listed class outstanding on Jun 30, 2026.

Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026
Buys0$0.00 disclosed value
Sells (SEC code S)25$2.04M disclosed value
25 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
Jun 22, 2026Form 4 · 10b5-1Schoenberg MarkChief Medical OfficerSellOrdinary Shares10.0K$35.01$350.1K129.8K
Jun 8, 2026Form 4Schoenberg MarkChief Medical OfficerSellOrdinary Shares5.2K$27.30$142.6K139.8K
May 8, 2026Form 4 · 10b5-1Schoenberg MarkChief Medical OfficerSellOrdinary Shares10.0K$30.00$300.0K135.0K
Feb 3, 2026Form 4Smith Jason DrewGeneral CounselSellOrdinary Shares3.2K$19.69$63.3K55.6K
Feb 3, 2026Form 4Smith Jason DrewGeneral CounselSellOrdinary Shares1.6K$19.69$31.7K51.3K
Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about URGN yet. Start the conversation.

Write the first post